Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wildflower Brands Inc. (WLDFF)
Vancouver, BC, CA
Wildflower Brands Inc. focuses on the development, design, and sale of branded cannabis goods within Washington and California. Their product line features a variety of hemp-derived CBD+ wellness items, such as topical creams, soaps, tinctures, capsules, and vaporizers. The company also offers specially curated bundle box kits. Customers can purchase these products directly through their online platform or from various retail partners. Previously known as Wildflower Marijuana Inc., the company adopted its current name, Wildflower Brands Inc., in April 2018. Its corporate headquarters are located in Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -99.99% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+403.2% ★ Q1'20: +108.1% (vs Q1'19)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+37.0% ★ Q1'20: +104.4% (vs Q1'19)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-109.9% Q1'20: +25.0% (vs Q1'19)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-55.5% Q1'20: +15.0% (vs Q1'19)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-7.2% Q1'20: +5.2% (vs Q1'19)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+15.1% Q1'20: +112.8% (vs Q1'19)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.42× Q1'20: 10.91× (vs Q1'19)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen W. Pearce | Chief Financial Officer, Corporate Secretary & Director | 17.4K | male |
| Amy Sugai | Vice President of Communication & Design | — | female |
| G. Scott Walker | Vice President of Corporate Development | — | male |
| Ken Oakes | National Sales Director | — | male |
| Krystian Wetulani | Chief Development Officer & Director | — | male |
| Myron Van Snick | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WLDFF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
